Highly Sensitive In Vivo Imaging of Trypanosoma brucei Expressing "Red-Shifted" Luciferase

PLoS Neglected Tropical Diseases

Volumn 7, Issue 11, 2013, Pages

  McLatchie, Alex P ^a   Burrell Saward, Hollie ^a   Myburgh, Elmarie ^b   Lewis, Michael D ^a   Ward, Theresa H ^a   Mottram, Jeremy C ^b   Croft, Simon L ^a   Kelly, John M ^a   Taylor, Martin C ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE;

5' UNTRANSLATED REGION; AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HOST PARASITE INTERACTION; IMMUNE RESPONSE; LIMIT OF DETECTION; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; TRYPANOSOMA BRUCEI;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; LUCIFERASES, FIREFLY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OPTICAL IMAGING; PARASITOLOGY; STAINING AND LABELING; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84888251381     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002571     Document Type: Article

References (25)

1. WHO (2012) Human African Trypanosomiasis (sleeping sickness). Factsheet No 259.
2. Wilkinson SR, Kelly JM, (2009) Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 11: e31.
3. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E, (2011) Drug resistance in human African trypanosomiasis. Future Microbiol 6: 1037-1047.
4. Checkley AM, Pepin J, Gibson WC, Taylor MN, Jager HR, et al. (2007) Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy. Trans R Soc Trop Med Hyg 101: 523-526.
5. Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, et al. (1995) Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 89: 92-97.
6. Jennings FW, Rodgers J, Bradley B, Gettinby G, Kennedy PG, et al. (2002) Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol Int 51: 381-388.
7. Lang T, Goyard S, Lebastard M, Milon G, (2005) Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 7: 383-392.
8. Hutchens M, Luker GD, (2007) Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 9: 2315-2322.
9. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5: e10777.
10. Luker GD, Luker KE, (2008) Optical imaging: current applications and future directions. J Nucl Med 49: 1-4.
11. Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, et al. (2010) Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal Biochem 396: 290-297.
12. Branchini BR, Southworth TL, Khattak NF, Michelini E, Roda A, (2005) Red- and green-emitting firefly luciferase mutants for bioluminescent reporter applications. Anal Biochem 345: 140-148.
13. Claes F, Vodnala SK, van Reet N, Boucher N, Lunden-Miguel H, et al. (2009) Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness. PLoS Negl Trop Dis 3: e486.
14. Giroud C, Ottones F, Coustou V, Dacheux D, Biteau N, et al. (2009) Murine Models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Negl Trop Dis 3: e509.
15. Myburgh E, Coles JA, Ritchie R, Hamilton A, Kennedy PGE, et al. (2013) In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis. PLoS Negl Trop Dis 7: e2384.
16. Hirumi H, Hirumi K, (1989) Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 75: 985-989.
17. Di Cristina M, Marocco D, Galizi R, Proietti C, Spaccapelo R, et al. (2008) Temporal and spatial distribution of Toxoplasma gondii differentiation into bradyzoites and tissue cyst formation in vivo. Infect Immun 76: 3491-3501.
18. Zomerdijk JC, Kieft R, Borst P, (1991) Efficient production of functional mRNA mediated by RNA polymerase I in Trypanosoma brucei. Nature 353: 772-775.
19. Michel G, Ferrua B, Lang T, Maddugoda MP, Munro P, et al. (2011) Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl Trop Dis 5: e1323.
20. Hyland KV, Asfaw SH, Olson CL, Daniels MD, Engman DM, (2008) Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol 38: 1391-1400.
21. Thalhofer CJ, Graff JW, Love-Homan L, Hickerson SM, Craft N, et al. (2010) In vivo imaging of transgenic Leishmania parasites in a live host. J Vis Exp (41) pii: 1980.
22. Jennings FW, (1992) Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol 43: 106-109.
23. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422.
24. De Gaudenzi JG, Noe G, Campo VA, Frasch AC, Cassola A, (2011) Gene expression regulation in trypanosomatids. Essays Biochem 51: 31-46.
25. Horn D, (2008) Codon usage suggests that translational selection has a major impact on protein expression in trypanosomatids. BMC Genomics 9: 2.